论文已发表
提 交 论 文
注册即可获取Ebpay生命的最新动态
注 册
IF 收录期刊
DRD2 和 COMT 基因多态性与下丘脑 - 垂体 - 甲状腺轴和下丘脑 - 垂体 - 性腺轴功能以及抗精神病药物所致高催乳素血症和巨催乳素血症之间的相关性
Authors Wang Z, Li J, Chen H, Jin H, Wang S, Hu X
Received 30 January 2025
Accepted for publication 3 May 2025
Published 8 May 2025 Volume 2025:21 Pages 1011—1017
DOI http://doi.org/10.2147/NDT.S518275
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Taro Kishi
Zhenhua Wang,1 Jing Li,2 Haizhi Chen,1 Haiying Jin,1 Shiliang Wang,1 Xuqiang Hu1
1Department of Psychiatry, Huzhou Third Municipal Hospital, the Affiliated Hospital of Huzhou University, Huzhou, Zhejiang, People’s Republic of China; 2Center for Disease Control and Prevention, Huzhou City, Zhejiang, People’s Republic of China
Correspondence: Xuqiang Hu, Department of psychiatry, Huzhou Third Municipal Hospital, the Affiliated Hospital of Huzhou University, Huzhou, Zhejiang, People’s Republic of China, Email huxuqiang@hz3rd-hosp.cn
Purpose: This study aimed to investigate the relationship between dopamine receptor D2 (DRD2) and catechol-o-methyltransferase (COMT) gene polymorphism, hypothalamic-pituitary-thyroid (HPT) and hypothalamic-pituitary-gonadal (HPG) axes functions, and macroprolactinemia induced by antipsychotics.
Patients and Methods: A total of 133 patients with schizophrenia were selected and given risperidone (4~6mg/d) monotherapy. The polymorphisms of DRD2 Taq1A and COMT Val158Met were analyzed using RFLP-PCR at baseline, and the levels of total prolactin (T-PRL), macroprolactin, C peptide (C-P), estradiol (E2), cholesterol (TC), low density lipoprotein (LDL), insulin, cortisol, thyroid function, and reproductive hormone were measured at baseline and the end of the fourth week of treatment. The patients were divided into a hyperprolactinemia group and a macroprolactinemia group according to their levels of T-PRL and macroprolactin, and the differences in the above indexes between the two groups were analyzed.
Results: There was no significant difference in the DRD2 Taq1A or COMT Val158Met gene polymorphisms between the two groups. However, after four weeks of treatment, significant differences were observed between the two groups in terms of C-P (t= 2.16, p=0.04), E2 (t=− 3.89, p< 0.001), TC (t= − 2.54, p=0.01), insulin (t=− 3.93, p< 0.001), T3 (t= 2.31, p= 0.02), and FT3 (t=2.05, p=0.04).
Conclusion: DRD2 Taq1A and COMT Val158Met gene polymorphisms may not be effective in predicting macroprolactinemia, but changes in C-P, E2, TC, insulin, T3 and FT3 levels may have some suggestive significance for the differentiation of hyperprolactinemia and macroprolactinemia.
Keywords: prolactin, macroprolactin, hyperprolactinemia, schizophrenia, gene polymorphism